Search | Clinical Trials Finder

Conditions: Safety and Tolerability
Interventions: inhaled human insulin, Insulin Lispro (Humalog U-100); Drug
Lead sponsor: Dance Biopharm Inc.; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Type 2 Diabetes
Interventions: Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: HDV-Lispro, Lispro; Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Huntington Beach, California • Pasadena, California • Tustin, California + 23 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Lispro Injection, Humalog; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anaheim, California • Fresno, California • Los Angeles, California + 52 more

Conditions: Type 2 Diabetes, Chronic Kidney Disease
Interventions: Dulaglutide, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 47
States / cities: Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart, Insulin Lispro; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Type 2 Diabetes
Interventions: Insulin Glargine, Metformin, Prandial insulin, Exenatide; Drug
Lead sponsor: University of Washington; Other
Eligibility: 40 Years to 75 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Viaject 7, LISPRO; Drug
Lead sponsor: Biodel; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 13 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Concord, California • Aurora, Colorado • Hollywood, Florida + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin Peglispro, Insulin Glargine, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Type 1
Interventions: LY900014, Insulin lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Fresno, California • Aurora, Colorado • Atlanta, Georgia

Conditions: Type1 Diabetes Mellitus
Interventions: HDV insulin lispro 100 UNIT/mL, Insulin Lispro 100 Units/mL; Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Bioequivalence in Healthy Subjects
Interventions: Insulin lispro; Biological
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type1 Diabetes Mellitus
Interventions: LY900014, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Atlanta, Georgia • Saint Louis Park, Minnesota

Conditions: Diabetes Mellitus, Type 1
Interventions: HDV-Insulin Lispro and Insulin Degludec (-40%), HDV-Insulin Lispro and Insulin Degludec (-10%); Drug
Lead sponsor: Diasome Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: San Mateo, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Type 1 Diabetes Mellitus
Interventions: SAR342434, insulin lispro; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Little Rock, Arkansas • Denver, Colorado

Conditions: Type 1 Diabetes
Interventions: Mylan's insulin glargine, Lantus®; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 72
States / cities: Bell Gardens, California • Fresno, California • Greenbrae, California + 64 more

Conditions: Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions: Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor; Drug · Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Up to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more

Conditions: Diabetes Mellitus
Interventions: Insulin Lispro, Regular Human Insulin, rHuPH20; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Rapid-Acting Insulin, Long acting insulin; Drug
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 15 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Lispro mix 75/25, Glargine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

Linagliptin Inpatient Trial

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Comparison of Insulins Aspart and Lispro in Insulin Pumps

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listro™) With Humalog® in Healthy Subjects

A Study of LY900014 in a Medtronic Pump

Comparison of Different Insulin Dosing Algorithms Using Hepatic Directed Vesicle-Insulin Lispro and Insulin Degludec

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine